Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Open Access
- 28 July 2021
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000), 000
- https://doi.org/10.14218/jcth.2021.00189
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new term from nonalcoholic fatty liver disease (NAFLD) and is a positive diagnosis based on histopathology, imaging, or blood biomarkers. MAFLD is one of the common causes of liver dysfunction worldwide, likely due to the increase in metabolic syndrome as well as the high burden of disease and its relationship to other extrahepatic conditions. However, effective pharmacological therapeutic agents are still lacking; current management largely focuses on weight reduction and lifestyle modification. The purpose of this review was to summarize the updated evidence of novel therapies targeting different pathogenetic pathways in MAFLD.Keywords
This publication has 53 references indexed in Scilit:
- The pan‐caspase inhibitor Emricasan (IDN‐6556) decreases liver injury and fibrosis in a murine model of non‐alcoholic steatohepatitisLiver International, 2014
- Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a reviewNutrition Journal, 2014
- Meta‐analysis: pioglitazone improves liver histology and fibrosis in patients with non‐alcoholic steatohepatitisAlimentary Pharmacology & Therapeutics, 2011
- The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseasesJournal of Advanced Pharmaceutical Technology & Research, 2011
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisThe New England Journal of Medicine, 2010
- What's in a NAme?Journal of Hepatology, 2009
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic SteatohepatitisGastroenterology, 2008
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory responseJournal of Hepatology, 2008
- Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid With Vitamin E in Nonalcoholic SteatohepatitisClinical Gastroenterology and Hepatology, 2006
- A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic SteatohepatitisThe New England Journal of Medicine, 2006